v3.26.1
Consolidated Statements of Cash Flows, Parent - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities    
Net income (loss) $ 1,603 $ 129
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities    
Depreciation, amortization, and accretion, including nuclear fuel and contract amortization 1,202 640
Deferred income taxes and amortization of ITCs 440 (98)
Net fair value changes related to derivatives (1,040) 356
Net realized and unrealized (gains) losses on NDT funds (17) (44)
Net realized and unrealized (gains) losses on equity investments 27 268
Other non-cash operating activities (199) 47
Changes in assets and liabilities:    
Accounts receivable 323 (15)
Inventories 106 98
Accounts payable and accrued expenses (1,377) (290)
Option premiums received (paid), net (15) 26
Collateral received (posted), net 249 (486)
Income taxes 103 120
Pension and non-pension postretirement benefit contributions (191) (174)
Other assets and liabilities (789) (470)
Net cash flows provided by (used in) operating activities 425 107
Cash flows from investing activities    
Capital expenditures (1,275) (806)
Proceeds from NDT fund sales 2,504 2,084
Investment in NDT funds (2,572) (2,152)
Acquisition of Calpine, net of cash and restricted cash acquired (2,537) 0
Other investing activities 148 (12)
Net cash flows provided by (used in) investing activities (3,732) (886)
Cash flows from financing activities    
Change in short-term borrowings 1,957 0
Proceeds from short-term borrowings with maturities greater than 90 days 3,000 0
Repayments of short-term borrowings with maturities greater than 90 days (1,500) 0
Issuance of long-term debt 2,770 0
Retirement of long-term debt (5,254) (57)
Dividends paid on common stock (155) (122)
Other financing activities (88) (229)
Net cash flows provided by (used in) financing activities 730 (408)
Increase (decrease) in cash, restricted cash, and cash equivalents (2,577) (1,187)
Cash, restricted cash, and cash equivalents at beginning of period 3,748 3,129
Cash, restricted cash, and cash equivalents at end of period 1,171 1,942
Supplemental disclosure of non-cash investing and financing activities    
Common stock issued for acquisition of Calpine 17,507 0
Exchange of Calpine senior notes for Constellation senior notes 2,290 0
Decrease in PP&E related to ARO update $ (889) $ (6)